On June 25, 2020, Fusion Pharmaceuticals announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share. All of the shares are being offered by Fusion. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Fusion, are expected to be $212.5 million.
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors.
Osler, Hoskin & Harcourt LLP advised Fusion Pharmaceuticals with a team consisting of Chad Bayne, Michael Grantmyre and Sahil Chopra (Emerging and High Growth Companies), Desmond Lee and Amy Sigurdson (Capital Markets), Andrew MacDougall (Corporate and Governance), Lynne Lacoursière and Kelly O'Ferrall (Executive Compensation), Shari Cohen (Employment & Labour), Tim Hughes (Tax) and Jacqueline Code (Research).